Labdane diterpenes protect against anoxia/reperfusion injury in cardiomyocytes: Involvement of AKT activation

Cell Death and Disease

Volumn 2, Issue 11, 2011, Pages

  Cuadrado, I ^a   Fernandez Velasco M ^b   Bosca L ^b   De Las Heras, B ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CSIC   (Spain)

Author keywords

AKT; AMPK; Apoptosis; Cardioprotection; ERK; Labdane diterpenes

Indexed keywords

14,15,16 TRISNOR 13,9ALPHA HISPANOLIDE; 8,9 DEHYDROHISPANOLONE 15,16 LACTOL; ADENYLATE KINASE; CASPASE 3; DEHYDROISOHISPANOLONE; DITERPENE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOXIA; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART PROTECTION; HOMEOSTASIS; INTRACELLULAR SIGNALING; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; ANIMAL; CELL HYPOXIA; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELL HYPOXIA; CELL SURVIVAL; DITERPENES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 83155176081     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.113     Document Type: Article

References (41)

1. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949-956. (Pubitemid 26359236)
2. Ruiz-Meana M, Garcia-Dorado D. Translational cardiovascular medicine (II). Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Rev Esp Cardiol 2009; 62: 199-209.
3. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005; 14: 170-175. (Pubitemid 40977859)
4. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009; 204: 334-341.
5. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 2011; 6: 12-13.
6. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006; 72: 152-162.
7. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemiareperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-460. (Pubitemid 38210151)
8. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009; 73: 1171-1177.
9. de las Heras B, Hortelano S, Giron N, Bermejo P, Rodriguez B et al. Kaurane diterpenes protect against apoptosis and inhibition of phagocytosis in activated macrophages. Br J Pharmacol 2007; 152: 249-255. (Pubitemid 47517606)
10. Castrillo A, de las Heras B, Hortelano S, Rodriguez B, Villar A et al. Inhibition of the nuclear factor kB pathway by tetracyclic kaurene diterpenes in macrophages. Specific effects on NF-kB-inducing kinase activity and on the coordinate activation of ERK and p38 MAPK. J Biol Chem 2001; 276: 15854-15860.
11. de las Heras B, Hortelano S. Molecular basis of the anti-inflammatory effects of terpenoids. Inflamm Allergy Drug Targets 2009; 8: 28-39.
12. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK et al. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 2010; 86: 103-112.
13. Chinou I. Labdanes of natural origin-biological activities (1981-2004). Curr Med Chem 2005; 12: 1295-1317.
14. Giron N, Traves PG, Rodriguez B, Lopez-Fontal R, Bosca L et al. Suppression of inflammatory responses by labdane-type diterpenoids. Toxicol Appl Pharmacol 2008; 228: 179-189.
15. Dong Y, Morris-Natschke SL, Lee KH. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep 2011; 28: 529-542.
16. Navarro A, de las Heras B, Villar AM. Andalusol, a diterpenoid with anti-inflammatory activity from Siderits foetens Clemen. Z Naturforsch C 1997; 52: 844-849. (Pubitemid 28094125)
17. de las Heras B, Navarro A, Diaz-Guerra MJ, Bermejo P, Castrillo A et al. Inhibition of NOS-2 expression in macrophages through the inactivation of NF-kB by andalusol. Br J Pharmacol 1999; 128: 605-612. (Pubitemid 29504750)
18. Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ. Role of p38a MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol 2005; 38: 617-623. (Pubitemid 40461825)
19. Qi D, Hu X, Wu X, Merk M, Leng L et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest 2009; 119: 3807-3816.
20. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133-1145.
21. Singh SS, Kang PM. Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases. Curr Pharm Des 2011; 17: 1783-1793.
22. Zhao Y, Zhao B. Protective effect of natural antioxidants on heart against ischemiareperfusion damage. Curr Pharm Biotechnol 2010; 11: 868-874.
23. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010; 106: 360-368.
24. Wang W, Lopaschuk GD. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Expert Rev Cardiovasc Ther 2007; 5: 1123-1134. (Pubitemid 350303047)
25. Carreira RS, Lee P, Gottlieb RA. Mitochondrial therapeutics for cardioprotection. Curr Pharm Des 2011; 17: 2017-2035.
26. Thomas CJ, Ng DC, Patsikatheodorou N, Limengka Y, Lee MW et al. Cardioprotection from ischaemia-reperfusion injury by a novel flavonol that reduces activation of p38 MAPK. Eur J Pharmacol 2011; 658: 160-167.
27. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M et al. Epigallocatechin-3- gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/ reperfusion-induced apoptosis. FASEB J 2004; 18: 1621-1623. (Pubitemid 39561653)
28. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M et al. Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sci 2011; 88: 725-729.
29. Li C, Tian J, Li G, Jiang W, Xing Y et al. Asperosaponin VI protects cardiac myocytes from hypoxia-induced apoptosis via activation of the PI3K/Akt and CREB pathways. Eur J Pharmacol 2010; 649: 100-107.
30. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914-922. (Pubitemid 46555697)
31. Takagi H, Matsui Y, Hirotani S, Sakoda H, Asano T et al. AMPK mediates autophagy during myocardial ischemia in vivo. Autophagy 2007; 3: 405-407. (Pubitemid 46986358)
32. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-1423. (Pubitemid 47417568)
33. Kupatt C, Hinkel R, Lamparter M, von Bruhl ML, Pohl T et al. Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase. Circulation 2005; 112: 117-122.
34. Matsui T, Tao J, del Monte F, Lee KH, Li L et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104: 330-335. (Pubitemid 32666956)
35. Wang Y, Gao E, Tao L, Lau WB, Yuan Y et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/ antinitrative protection of adiponectin. Circulation 2009; 119: 835-844.
36. Russell 3rd RR, Li J, Coven DL, Pypaert M, Zechner C et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503. (Pubitemid 39572099)
37. García-Álvarez M, Pérez-Sirvent L, Rodriguez B. Transformaciones de hispanolona I. Síntesis parcial del diterpenoide furolabdánico galeopsinas. Anales Quím 1981; 77: 316-319.
38. Pérez-Sirvent L, García-Álvarez MC, Rodríguez B. Transformaciones de hispanolona II. Reaccio'n retroaldo'lica de hispanolona y condensacio'n aldo'lica de d-dicetonas diterpénicas. Anales Quím 1981; 77: 324-329.
39. Pérez-Sirvent L, García-Álvarez MC, Balestrieri MA, Rodríguez B. Transformaciones de hispanolona III. Reacciones del anillo B y degradacio'n a di-homo-drimanos. Anales Quím 1981; 77: 330-334.
40. Fernandez-Velasco M, Goren N, Benito G, Blanco-Rivero J, Bosca L et al. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol 2003; 553: 395-405. (Pubitemid 37527543)
41. Mossman T. Rapid colorimetric assay for cellular growth and survivals: application to proliferation and cytotoxicity assays. J Immunol Methods 1983: 55-63.